Commentary on 'The DOPPS practice monitor for US dialysis care: Update on trends in anemia management 2 years into the bundle': Iron(y) abounds 2 years later

American Journal of Kidney Diseases

Volumn 62, Issue 6, 2013, Pages 1217-1220

  Weiner, Daniel E ^a   Winkelmayer, Wolfgang C ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIALYSIS; DRUG MEGADOSE; EQUIPOISE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MEDICAID; MEDICARE; NOTE; OUTCOME ASSESSMENT; PATIENT CARE; PREVALENCE; PROSPECTIVE PAYMENT; REIMBURSEMENT; UNITED STATES; CAPITATION FEE; CARE BUNDLE; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DOSE RESPONSE; ECONOMICS; FOLLOW UP; FORECASTING; GOVERNMENT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; METABOLISM; TREATMENT OUTCOME; TRENDS;

ANEMIA; CAPITATION FEE; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FOLLOW-UP STUDIES; FORECASTING; HEMATINICS; HEMODIALYSIS UNITS, HOSPITAL; HEMOGLOBINOMETRY; HUMANS; INFUSIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT CARE BUNDLES; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE PAYMENT SYSTEM; TRANSFERRIN; UNITED STATES;

EID: 84888314489     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.10.006     Document Type: Editorial

References (28)

1. Centers for Medicare & Medicaid Services Medicare program; end-stage renal disease prospective payment system. Final rule Fed Regist 75 155 2010 49029 49214
2. Centers for Medicare & Medicaid Services Medicare program; end-stage renal disease quality incentive program. Final rule Fed Regist 76 3 2011 627 646
3. J.D. Chambers, D.E. Weiner, S.K. Bliss, and P.J. Neumann What can we learn from the U.S. expanded end-stage renal disease bundle? Health Policy 110 2-3 2013 164 171
4. A.R. Nissenson, F.W. Maddux, R.L. Velez, T. Mayne, and J. Parks Accountable care organizations and ESRD: the time has come Am J Kidney Dis 59 5 2012 724 733
5. S. Watnick, D.E. Weiner, R. Shaffer, J. Inrig, S. Moe, and R. Mehrotra Comparing mandated health care reforms: the Affordable Care Act, accountable care organizations, and the Medicare ESRD program Clin J Am Soc Nephrol 7 9 2012 1535 1543
6. W.C. Winkelmayer, and G.M. Chertow The 2011 ESRD prospective payment system: an uncontrolled experiment Am J Kidney Dis 57 4 2011 542 546
7. L.T. Pizzi, T.J. Bunz, D.W. Coyne, D.S. Goldfarb, and A.K. Singh Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation Kidney Int 74 12 2008 1588 1595
8. US Food and Drug Administration. FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. June 24, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed March 16, 2012.
9. D.A. Goodkin, D.S. Fuller, and B.M. Robinson Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients J Am Soc Nephrol 22 2 2011 358 365
10. R.L. Pisoni, J.L. Bragg-Gresham, and D.S. Fuller Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): associations with mortality, patient characteristics, and facility practices Am J Kidney Dis 57 2 2011 266 275
11. M.A. Pfeffer, E.A. Burdmann, and C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
12. A.K. Singh, L. Szczech, and K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 20 2006 2085 2098 (Pubitemid 44749317)
13. D.M. Spiegel, I. Khan, M. Krishnan, and T.J. Mayne Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008 Am J Kidney Dis 55 1 2010 113 120
14. D.E. Weiner, and W.C. Winkelmayer Commentary on 'The DOPPS Practice Monitor for US dialysis care: trends through August 2011': an ESA confluence Am J Kidney Dis 60 1 2012 165 167
15. D.S. Fuller, R.L. Pisoni, B.A. Bieber, B.W. Gillespie, and B.M. Robinson The DOPPS Practice Monitor for US dialysis care: trends through December 2011 Am J Kidney Dis 61 2 2013 342 346
16. D.S. Fuller, R.L. Pisoni, B.A. Bieber, F.K. Port, and B.M. Robinson The DOPPS Practice Monitor for US dialysis care: update on trends in anemia management 2 years into the bundle Am J Kidney Dis 62 6 2013 1213-1216
17. A.V. Kshirsagar, J.K. Freburger, A.R. Ellis, L. Wang, W.C. Winkelmayer, and M.A. Brookhart The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients Am J Med 126 6 2013 541.e1 541.e14
18. Arbor Research Collaborative for Health. DOPPS Practice Monitor, August 2013. Available at: http://www.dopps.org/DPM/Default.aspx. Accessed September 3, 2013.
19. T. Kapoian, N.B. O'Mara, and A.K. Singh Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin J Am Soc Nephrol 19 2 2008 372 379 (Pubitemid 351240658)
20. D.W. Coyne, T. Kapoian, and W. Suki Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J Am Soc Nephrol 18 3 2007 975 984 (Pubitemid 46434515)
21. Arbor Research Collaborative for Health/University of Michigan Kidney Epidemiology and Cost Center. End-Stage Renal Disease (ESRD) Quality Measure Development and Maintenance. Clinical Technical Expert Panel Draft Summary Report. Submitted to CMS September 14, 2012. Contract No. HHSM-500-2008-000221, Task Order No. HHSM-500-T0001. Available at: http://www.dialysisreports.org/pdf/ esrd/public-measures/Final-TEP-Summary-Report-10252012-508.pdf. Accessed Septermber 3, 2013.
22. Centers for Medicare & Medicaid Services. Medicare program; end-stage renal disease prospective payment system, quality incentive program, and durable medical equipment, prosthetics, orthotics, and supplies; proposed rule. Fed Regist. 2013;78(130):40836-40890.
23. D.E. Weiner, and D.C. Miskulin Anemia management in chronic kidney disease: bursting the hemoglobin bubble Ann Intern Med 153 1 2010 53 55
24. A.S. Kliger, R.N. Foley, and D.S. Goldfarb KDOQI US Commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD Am J Kidney Dis 62 5 2013 849 859
25. M.A. Brookhart, J.K. Freburger, A.R. Ellis, L. Wang, W.C. Winkelmayer, and A.V. Kshirsagar Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients J Am Soc Nephrol 24 7 2013 1151 1158
26. S.L. Goldstein, D. Morris, and B.A. Warady Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial Am J Kidney Dis 61 4 2013 588 597
27. Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease Kidney Int Suppl 2 2012 279 335
28. L.M. Moist, S. Troyanov, and C.T. White Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD Am J Kidney Dis 62 5 2013 860 873